Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | AGER | Q15109 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | DHODH | Q02127 | 3/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574424 | 1.00 | NAPRT (1.00) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL19280924 | 1.00 | NAPRT (1.00) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL4407488 | 0.98 | NAPRT (0.96) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Nitrous Acid SCHEMBL28824677 | 0.92 | NAPRT (0.85) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL6224044 | 0.91 | NAPRT (0.82) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Glycine SCHEMBL29042666 | 0.89 | NAPRT (0.79) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL27791125 | 0.86 | NAPRT (0.74) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL27612856 | 0.84 | NAPRT (0.73) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL2045679 | 0.83 | NAPRT (0.71) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL28705950 | 0.83 | NAPRT (0.70) | NAPRTKDM4ETDP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 822 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| CN-119462646-A | Substituted tetrahydro-beta-carboline derivative, synthesis method and application thereof | 江苏科技大学 | 2025-02-18 | — | — | CN | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| CN-113912534-B | Biphenyl heterocyclic compound, synthesis method and application thereof | 江苏科技大学 | 2023-07-25 | — | — | CN | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| WO-2023083161-A1 | BIPHENYL HETEROCYCLIC COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 江苏科技大学 | 2023-05-19 | — | — | WO | claimed |
| CN-113980025-B | Nicotine and indole hybrid compound, and synthesis method and application thereof | 江苏科技大学 | 2023-02-24 | — | — | CN | claimed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-113880847-B | Cyclotryptamine alkaloid, and synthesis method and application thereof | 江苏科技大学 | 2023-02-03 | — | — | CN | claimed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | claimed |
| CN-113912592-A | Honokiol dihydrofuran ester derivative, preparation method and application thereof | 西北农林科技大学 | 2022-01-11 | — | — | CN | claimed |
| CN-113912534-A | Biphenyl heterocyclic compound, and synthesis method and application thereof | 江苏科技大学 | 2022-01-11 | — | — | CN | claimed |
| CN-113880847-A | Cyclotryptamine alkaloid, and synthesis method and application thereof | 江苏科技大学 | 2022-01-04 | — | — | CN | claimed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| CN-113046734-A | Bivalent palladium complex solution and preparation method and application thereof | 上海天承化学有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-110330454-B | Synthesis method of pyridine heterocyclic azobenzene | 北华航天工业学院 | 2021-05-14 | — | — | CN | claimed |
| CN-105670607-B | Pb in one kind detection environment2+Fluorine-containing fluorescent optical sensor and its preparation and application | 同济大学 | 2017-10-24 | — | — | CN | claimed |
| CN-105670607-A | Novel fluorine-containing fluorescent sensor for detecting Pb<2+> in environment, preparation and method thereof | 同济大学 | 2016-06-15 | — | — | CN | claimed |
| US-5430049-A | Treating hyperproliferative disorders | GAUT ZANE N (US) | 1995-07-04 | — | — | US | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| CN-119528903-A | Compounds for the treatment of spinal muscular atrophy | PTC医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-3551631-B9 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2025-02-26 | — | — | EP | disclosed |
| CN-119462646-A | Substituted tetrahydro-beta-carboline derivative, synthesis method and application thereof | 江苏科技大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-119462645-A | Tetrahydro-beta-carboline bacteriostatic agent, and synthesis method and application thereof | 江苏科技大学 | 2025-02-18 | — | — | CN | disclosed |
| EP-4494705-A2 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2025-01-22 | — | — | EP | disclosed |
| EP-4480541-A2 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Lighthouse Pharmaceuticals, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| EP-3551631-B1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-11-13 | — | — | EP | disclosed |
| US-12110263-B2 | Ketone inhibitors of lysine gingipain | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-3512846-B1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-118271285-A | Azetidine-containing amide derivative, preparation method and application thereof | 贵州大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-115073447-B | Berberine type pyridine carboxylic acid quaternary ammonium salt compound and application thereof in preparation of medicines | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | disclosed |
| US-20240174663-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2024-05-30 | — | — | US | disclosed |
| CN-115279368-B | Heteroaryl compounds | 维瓦斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118055930-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024063578-A1 | NOVEL TETRAHETEROCYCLE COMPOUND | 일동제약(주) | 2024-03-28 | — | — | WO | disclosed |
| CN-114585628-B | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20240034722-A1 | PRETARGETING IMAGING AGENTS | ELI LILLY AND COMPANY | 2024-02-01 | — | — | US | disclosed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| EP-4301751-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | King's College London (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARAMCEUTICA NV (BE) | 2023-12-28 | — | — | US | disclosed |
| CN-117295724-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-12-21 | — | — | US | disclosed |
| CN-109983012-B | Ketone inhibitors of lysine gum protease | 莱特豪斯制药公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-4262885-A1 | PRETARGETING IMAGING AGENTS | Eli Lilly and Company (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-113773288-B | Heterocyclic dehydroabietyl formamide compound and preparation method and application thereof | 南京林业大学 | 2023-09-29 | — | — | CN | disclosed |
| EP-4244224-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783177-A | Pretargeting imaging agent | 伊莱利利公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116730982-A | Bactericide and preparation method thereof | 广东灵思妙用智能科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230257727-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| CN-113912534-B | Biphenyl heterocyclic compound, synthesis method and application thereof | 江苏科技大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-112533646-B | Contrast agent composition for targeting angiogenesis and preparation method thereof | 韩国基础科学支援研究院 | 2023-07-25 | — | — | CN | disclosed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| CN-112745237-B | 2-arylamine compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| US-20230174510-A1 | N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof | EMORY UNIVERSITY | 2023-06-08 | — | — | US | disclosed |
| CN-113980027-B | Fluorine-containing heterocyclic compound, preparation method and application thereof | 江苏科技大学 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023083161-A1 | BIPHENYL HETEROCYCLIC COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 江苏科技大学 | 2023-05-19 | — | — | WO | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023061415-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | WO | disclosed |
| US-20230106583-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-113912592-B | Honokiol dihydrofuran ester derivative, preparation method and application thereof | 西北农林科技大学 | 2023-03-10 | — | — | CN | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| CN-113980025-B | Nicotine and indole hybrid compound, and synthesis method and application thereof | 江苏科技大学 | 2023-02-24 | — | — | CN | disclosed |
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-113880847-B | Cyclotryptamine alkaloid, and synthesis method and application thereof | 江苏科技大学 | 2023-02-03 | — | — | CN | disclosed |
| US-20230021091-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| CN-115397806-A | Aryl and heteroaryl compounds and their therapeutic use in conditions associated with altered activity of galactocerebrosidase | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220372018-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-11-08 | — | — | US | disclosed |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-03 | — | — | US | disclosed |
| CN-115279368-A | Heteroaryl compounds | 维瓦斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-06 | — | — | US | disclosed |
| EP-4065546-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | Gain Therapeutics SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| EP-4061364-A1 | HETEROARYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-115068473-A | Application of berberine type pyridine carboxylic acid quaternary ammonium salt compound in resisting virus infection diseases | 中国医学科学院药物研究所 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073447-A | Berberine type pyridine carboxylic acid quaternary ammonium salt compound and application thereof in preparing medicines | 中国医学科学院药物研究所 | 2022-09-20 | — | — | CN | disclosed |
| US-20220289727-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-4056562-A1 | HETEROCYCLIC INHIBITORS OF BRUTON'S TYROSINE KINASE | Merck Patent GmbH (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| US-11427814-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4017850-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022132924-A1 | PRETARGETING IMAGING AGENTS | ELI LILLY AND COMPANY (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013759-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4007638-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114585628-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022104348-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-19 | — | — | WO | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-2718270-B1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-114391012-A | Pyridine derivatives as KIF18A inhibitors | 美国安进公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-113046734-B | Bivalent palladium complex solution and preparation method and application thereof | 上海天承化学有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114258392-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-112979672-B | 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof | 郑州大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-114127062-A | Thiadiazolyl derivatives as inhibitors of DNA polymerase Theta | 伊迪亚生物科学有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-110317204-B | Pyrazolopyrimidinone derivative and preparation method and application thereof | 安徽农业大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-110317204-B | Pyrazolopyrimidinone derivative and preparation method and application thereof | 安徽农业大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-109988169-B | Octahydropyrrolo [3,4-c ] pyrrole derivatives and uses thereof | 广东东阳光药业有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113980025-A | Nicotine and indole hybrid compound, and synthesis method and application thereof | 江苏科技大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-113980027-A | Fluorine-containing heterocyclic compound, preparation method and application thereof | 江苏科技大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-113912592-A | Honokiol dihydrofuran ester derivative, preparation method and application thereof | 西北农林科技大学 | 2022-01-11 | — | — | CN | disclosed |
| CN-113912534-A | Biphenyl heterocyclic compound, and synthesis method and application thereof | 江苏科技大学 | 2022-01-11 | — | — | CN | disclosed |
| CN-113880847-A | Cyclotryptamine alkaloid, and synthesis method and application thereof | 江苏科技大学 | 2022-01-04 | — | — | CN | disclosed |
| CN-113773288-A | Heterocyclic ring-containing dehydroabietyl formamide compounds and preparation method and application thereof | 南京林业大学 | 2021-12-10 | — | — | CN | disclosed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-109369634-B | Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity | 陕西国际商贸学院 | 2021-07-27 | — | — | CN | disclosed |
| US-20210214701-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-07-15 | — | — | US | disclosed |
| CN-113046734-A | Bivalent palladium complex solution and preparation method and application thereof | 上海天承化学有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-112979672-A | 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof | 郑州大学 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021105906-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105906-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021102204-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102204-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| CN-110330454-B | Synthesis method of pyridine heterocyclic azobenzene | 北华航天工业学院 | 2021-05-14 | — | — | CN | disclosed |
| CN-110330454-B | Synthesis method of pyridine heterocyclic azobenzene | 北华航天工业学院 | 2021-05-14 | — | — | CN | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021026100-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026100-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| CN-112279808-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112250627-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-22 | — | — | CN | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-107690281-B | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-110590661-B | Osthole ester derivative, and preparation method and application thereof | 郑州大学 | 2020-10-02 | — | — | CN | disclosed |
| CN-111642504-A | Quinoline 4-hydroxypyridine formate compound and application thereof in preventing and treating rice blast germs | 杨子辉 | 2020-09-11 | — | — | CN | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| CN-106715395-B | 6-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as TAAR modulators | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-106831732-B | Compositions and methods for producing pyrimidine and pyridine compounds having BTK inhibitory activity | 默克专利有限公司 | 2019-12-24 | — | — | CN | disclosed |
| CN-110590661-A | Osthole ester derivative, and preparation method and application thereof | 郑州大学 | 2019-12-20 | — | — | CN | disclosed |
| EP-3551631-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | The University of Sydney (AU) | 2019-10-16 | — | — | EP | disclosed |
| EP-3030233-B1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3030233-B1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10435398-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435398-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10413562-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3512846-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| US-10308645-B2 | Piperidine oxadiazole and thiadiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308645-B2 | Piperidine oxadiazole and thiadiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3154978-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | LOXO ONCOLOGY INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10239838-B2 | Heteroaryl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239838-B2 | Heteroaryl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2018234483-A1 | TUNABLE PROBES FOR SELECTIVE PROTEIN LABELLING AND ENZYME INHIBITION | AAA CHEMISTRY APS (DK) | 2018-12-27 | — | — | WO | disclosed |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| US-10155750-B2 | Amidoethyl azole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3174853-B1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180243324-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010539-B2 | Pyrazole, triazole and tetrazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010539-B2 | Pyrazole, triazole and tetrazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010539-B2 | Pyrazole, triazole and tetrazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2018107216-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2018-06-21 | — | — | WO | disclosed |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9957229-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957261-B2 | 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-9920038-B2 | Methyl oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920038-B2 | Methyl oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920038-B2 | Methyl oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2632460-B1 | THIOPHENE DERIVATIVES FOR USE IN THE TREATMENT OF TUBERCULOSIS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2017-12-28 | — | — | US | disclosed |
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2017-12-28 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-9828368-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828368-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828368-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170320856-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320856-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320856-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320865-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319560-A1 | PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319560-A1 | PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320865-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319560-A1 | PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320865-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170313693-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313693-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313693-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| CN-105670607-B | Pb in one kind detection environment2+Fluorine-containing fluorescent optical sensor and its preparation and application | 同济大学 | 2017-10-24 | — | — | CN | disclosed |
| US-9790183-B2 | Pyridyl inhibitors of hedgehog signalling | GENENTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2017162840-A1 | SENSITIZATION OF CANCER CELLS TO NAMPT INHIBITORS BY NICOTINIC ACID PHOSPHORIBOSYLTRANSFERASE NEUTRALIZATION | UNIVERSITÀ DEGLI STUDI DI GENOVA (IT) | 2017-09-28 | — | — | WO | disclosed |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260136-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260136-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260136-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3203840-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2111756-B1 | PEST CONTROL AGENTS | MEIJI SEIKA PHARMA CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| EP-3174853-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-9670154-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170137416-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
| EP-2668186-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| EP-3154978-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Redx Pharma Plc (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9580449-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20170015627-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| EP-2528917-B1 | PYRAZOLOPYRIDINES USEFUL FOR THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR (HYPER)PROLIFERATIVE DISEASES | VERTEX PHARMA (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016144792-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ALPHARMAGEN, LLC (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144797-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ALPHARMAGEN, LLC (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016101118-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106105-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106105-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016101118-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2016100162-A2 | 5,5-BICYCLIC OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100156-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016095205-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100161-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016100161-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100162-A2 | 5,5-BICYCLIC OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100157-A2 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016095205-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016100157-A2 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100156-A1 | HETEROARYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| EP-3030233-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-06-15 | — | — | EP | disclosed |
| CN-105670607-A | Novel fluorine-containing fluorescent sensor for detecting Pb<2+> in environment, preparation and method thereof | 同济大学 | 2016-06-15 | — | — | CN | disclosed |
| WO-2016089722-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089722-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016086357-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016086358-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016086358-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016086357-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160152569-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2016085784-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085783-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085783-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2016065584-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065584-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065585-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065586-A1 | PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069517-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069515-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065585-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069510-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065583-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069512-A1 | PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065583-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065586-A1 | PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-9321761-B2 | Pyridyl inhibitors of hedgehog signalling | CURIS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9278961-B2 | Pyridyl inhibitors of hedgehog signalling | GENENTECH, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2016016162-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2015189620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | REDX PHARMA PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| CN-105017240-A | Pesticidal compositions | DOW AGROSCIENCES LLC | 2015-11-04 | — | — | CN | disclosed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| CN-104884445-A | Benzamides | LUNDBECK & CO AS H | 2015-09-02 | — | — | CN | disclosed |
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| US-9073947-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9067932-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| CN-102458403-B | Insecticidal composition | DOW AGROSCIENCES LLC | 2015-06-03 | — | — | CN | disclosed |
| US-20150111879-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | CURIS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150105550-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | CURIS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| EP-2854787-A2 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2015018029-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015020930-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015020930-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015018029-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2408770-B1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | Univ Virginia Patent Found (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2408770-B1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | Univ Virginia Patent Found (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8802703-B2 | Arylamino N-heteraryl compounds as MEK inhibitors | MERCK SERONO S.A. (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| CN-102161607-B | Method for preparing fluorine-containing aromatic compound | UNIV SOUTH CHINA AGRICULT | 2014-07-30 | — | — | CN | disclosed |
| CN-102203065-B | Novel phenylamide or pyridylamide derivatives and their use as GPBAR1 agonists | HOFFMANN LA ROCHE | 2014-07-09 | — | — | CN | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| CN-102414177-B | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-07-02 | — | — | CN | disclosed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8716309-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | disclosed |
| EP-2718270-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | Merck Patent GmbH (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| CN-103562205-A | Inhibitors of influenza viruses replication | VERTEX PHARMA | 2014-02-05 | — | — | CN | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2668186-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130317070-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130317059-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177536-A2 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-2649070-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| EP-2647620-A1 | STABLE SYNTHETIC INTERMEDIATE AND METHOD FOR MANUFACTURING SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-2632460-A2 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | University Of Virginia Patent Foundation (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2421366-B1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137703-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137703-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137703-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2313372-B1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2313372-B1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| US-8404679-B2 | Pyrrolidine derivatives as NK2 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| CN-102947305-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC | 2013-02-27 | — | — | CN | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012170976-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2066662-B1 | SERINE HYDROLASE INHIBITORS | KYORIN SEIYAKU KK (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2528917-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2066662-B1 | SERINE HYDROLASE INHIBITORS | KYORIN SEIYAKU KK (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8293744-B2 | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| CN-102686572-A | Oxazoline derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120208803-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | BISSANTZ CATERINA (FR) | 2012-08-16 | — | — | US | disclosed |
| WO-2012102580-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-08-02 | — | — | WO | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| CN-101501002-B | Non-nucleoside reverse transcriptase inhibitors | HOFFMANN LA ROCHE | 2012-06-27 | — | — | CN | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094980-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GUNZNER JANET L (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040170-A2 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| CN-102369188-A | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH | 2012-03-07 | — | — | CN | disclosed |
| EP-2421366-A1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-02-09 | — | — | US | disclosed |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-02-09 | — | — | US | disclosed |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-02-09 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2408770-A2 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | University Of Virginia Patent Foundation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8063064-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| CN-102161607-A | Method for preparing fluorine-containing aromatic compound | UNIV SOUTH CHINA AGRICULT | 2011-08-24 | — | — | CN | disclosed |
| US-20110201602-A1 | PROTEIN KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-102149681-A | Piperazine derivatives for binding and imaging amyloid plaques and their use | BAYER SCHERING PHARMA AG | 2011-08-10 | — | — | CN | disclosed |
| WO-2011094273-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-2350000-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2350045-A1 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110183966-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183966-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183966-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110178396-A1 | Nicotinamide Derivatives | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2011-07-21 | — | — | US | disclosed |
| WO-2011075747-A1 | THERAPEUTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075747-A1 | THERAPEUTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| CN-102066321-A | Pyrrolidine derivatives as NK2 receptor antagonists | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2313372-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092461-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | CURIS ROYALTY LLC | 2011-04-21 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7928106-B2 | 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2057125-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-2297098-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110059975-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | KENNEDY-SMITH JOSHUA | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2285778-A1 | NICOTINAMIDE DERIVATIVES | CRC for Biomedical Imaging Development Ltd (AU) | 2011-02-23 | — | — | EP | disclosed |
| US-7888364-B2 | Pyridyl inhibitors of hedgehog signalling | CURIS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20110034404-A1 | PEST CONTROL AGENTS | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-7880000-B2 | N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis | AMGEN INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2271642-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | Genentech, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010123716-A1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-2231625-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | disclosed |
| WO-2010107736-A2 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2225227-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2222161-A1 | QUINOXALINYL DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7772233-B2 | Arylamino N-heteroaryl compounds as MEK inhibitors | Merck Serono, S.A. (CH) | 2010-08-10 | — | — | US | disclosed |
| WO-2010081036-A2 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2205589-A2 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2029601-B1 | PYRIDOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-7713974-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| WO-2010028776-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-18 | — | — | WO | disclosed |
| EP-2163541-A1 | Piperazine derivatives for binding and imaging amyloid plaques and their use | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010017350-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017350-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2139895-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009153179-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312327-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2121613-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009129573-A1 | NICOTINAMIDE DERIVATIVES | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129573-A1 | NICOTINAMIDE DERIVATIVES | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009126863-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-7598412-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598412-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598412-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| CN-101535304-A | Serine hydrolase inhibitors | ACTIVX BIOSCIENCES INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7572801-B2 | Pyridopyrimidinone derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2009-08-06 | — | — | US | disclosed |
| CN-101501002-A | Non-nucleoside reverse transcriptase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| EP-2079734-A1 | OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NeuroSearch A/S (DK) | 2009-07-22 | — | — | EP | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2009073713-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-2066662-A2 | SERINE HYDROLASE INHIBITORS | Activx Biosciences, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2009028899-A1 | 1'-ALKYLPIPERIDINE-4'-SPIRO-2-6-(AMIDO)-2H-BENZOPYRAN DERIVATIVES HAVING ANTICANCER ACTIVITY | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-03-05 | — | — | WO | disclosed |
| EP-2029601-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-2004625-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2008116742-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1960518-A2 | ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1960367-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
| CN-101223169-A | Pyrrolo [2, 3-b ] pyridine derivative protein kinase inhibitors | PLEXXIKON INC (US) | 2008-07-16 | — | — | CN | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1937682-A1 | MET KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| WO-2008049864-A1 | OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008036379-A2 | SERINE HYDROLASE INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036379-A2 | SERINE HYDROLASE INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1896463-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20080045511-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| WO-2008013334-A1 | DEFORMYLASE INHIBITOR, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION COMPRISING THE SAME | PROMEDITECH INC. (KR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | HOFFMAN-LA ROCHE INC | 2007-11-29 | — | — | US | disclosed |
| WO-2007134986-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007123939-A2 | NOVEL ARYLAMINO N-HETERARYLS AS MEK INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067559-A2 | ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-1789390-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | Genentech, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007028456-A1 | SUBSTITUTED PYRIDOCARBOXAMIDES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) | BAYER HEALTHCARE AG (DE) | 2007-03-15 | — | — | WO | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1906177-A | Process for preparing pyridopyrimidinones | SCIOS INC (US) | 2007-01-31 | — | — | CN | disclosed |
| WO-2007009635-A1 | PHENYL SUBSTITUTED PIPERAZINE-DERIVATIVES AS INHIBITORS OF PLAMINOGENIC ACTIVATOR INHIBITORS-I (PAI-I) | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| CN-1886393-A | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups | VERTEX PHARMA (US) | 2006-12-27 | — | — | CN | disclosed |
| WO-2006123249-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7105682-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7102009-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060194848-A1 | e.g. 2-(1H-indazol-6-ylamino)-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide; angiogenesis inhibitors, antiproliferative or anticarcinogenic agents | AMGEN INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1680411-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CONTAINING CYCLOALKYL OR PYRANYL GROUPS | Vertex Pharmaceuticals Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | CURIS ROYALTY LLC | 2006-03-23 | — | — | US | disclosed |
| WO-2006028958-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050148648-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005035514-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CONTAINING CYCLOALKYL OR PYRANYL GROUPS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-21 | — | — | WO | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1466898-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| CN-1096459-C | (R) -5-bromo-N- (1-ethyl-4-methylhexahydro-1H-1, 4-diaza * -6-yl) -2-methoxy-6-methylamino-3-pyridinecarboxamide, process for preparing same and pharmaceutical composition containing same | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-12-18 | — | — | CN | disclosed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0846684-A3 | Process for producing 2-halo-nicotinic acid derivatives and precursors thereto | REILLY INDUSTRIES, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| CN-1192213-A | (R) -5-bromo-N- (1-ethyl-4-methylhexahydro-1H-1, 4-diaza-6-yl) -2-methoxy-6-methylamino-3-pyridinecarboxamide, process for preparing same and pharmaceutical composition containing same | DAINIPPON PHARMACEUTICAL CO (JP) | 1998-09-02 | — | — | CN | disclosed |
| EP-0846684-A2 | Process for producing 2-halo-nicotinic acid derivatives and precursors thereto | REILLY INDUSTRIES, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5630962-A | 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| US-5430049-A | Treating hyperproliferative disorders | GAUT ZANE N (US) | 1995-07-04 | — | — | US | disclosed |
| CN-1023680-C | Herbicidal pyridine sulfonylureas | DU PONT (US) | 1994-02-09 | — | — | CN | disclosed |
| EP-0506729-A1 | PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS | Beecham Group p.l.c. (GB) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009856-A1 | PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS | BEECHAM GROUP PLC (GB) | 1991-07-11 | — | — | WO | disclosed |
| CN-87107320-A | Herbicidal pyridine sulfonylureas | — | 1988-12-07 | — | — | CN | disclosed |
| CN-87107320-A | Herbicidal pyridine sulfonylureas | — | 1988-12-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | NAPRT 2475/4885KDM4E 215/4885TDP1 1585/4885 |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | NAPRT 1424/4885KDM4E 1783/4885TDP1 1448/4885 |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | NAPRT 4651/4885KDM4E 941/4885TDP1 3773/4885 |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | NAPRT 988/4885KDM4E 683/4885TDP1 2694/4885 |
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | NAPRT 3002/4885KDM4E 4541/4885TDP1 958/4885 |
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | NAPRT 1462/4885KDM4E 856/4885TDP1 185/4885 |
| US-12110263-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | NAPRT 2475/4885KDM4E 215/4885TDP1 1585/4885 |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NAPRT 2917/4885KDM4E 4063/4885TDP1 2133/4885 |
| US-20150105550-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | NAPRT 2354/4885KDM4E 411/4885TDP1 3293/4885 |
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | NAPRT 1808/4885KDM4E 990/4885TDP1 768/4885 |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | NAPRT 3872/4885KDM4E 3719/4885TDP1 125/4885 |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | NAPRT 78/4885KDM4E 1342/4885TDP1 4029/4885 |
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | NAPRT 2167/4885KDM4E 3067/4885TDP1 4176/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | NAPRT 1808/4885KDM4E 990/4885TDP1 768/4885 |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | NAPRT 113/4885KDM4E 1056/4885TDP1 1883/4885 |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAPRT 1990/4885KDM4E 3505/4885TDP1 2835/4885 |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NAPRT 2197/4885KDM4E 1618/4885TDP1 3653/4885 |
| US-20150111879-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | NAPRT 2354/4885KDM4E 411/4885TDP1 3293/4885 |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | HCRTR1, HCRTR2, OXTR | NAPRT 2025/4885KDM4E 2298/4885TDP1 4544/4885 |
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GBA1, GALC, MAN2B1 | NAPRT 3000/4885KDM4E 3268/4885TDP1 999/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | NAPRT 1808/4885KDM4E 990/4885TDP1 768/4885 |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | NAPRT 904/4885KDM4E 3269/4885TDP1 4160/4885 |
| US-20050148648-A1 | Modulators of ATP-binding cassette transporters | ABCB11, ABCB1, ABCC5 | NAPRT 388/4885KDM4E 4529/4885TDP1 3251/4885 |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | NAPRT 2354/4885KDM4E 411/4885TDP1 3293/4885 |
| US-20080045511-A1 | Non-nucleoside reverse transcriptase inhibitors | ADORA2B, ADORA1, ADORA3 | NAPRT 335/4885KDM4E 917/4885TDP1 750/4885 |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NAPRT 2272/4885KDM4E 924/4885TDP1 3967/4885 |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | NAPRT 2399/4885KDM4E 2973/4885TDP1 4837/4885 |
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | ABCB11, ABCB1, ABCC5 | NAPRT 388/4885KDM4E 4529/4885TDP1 3251/4885 |
| US-20230174510-A1 | N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof | BDNF, NTRK2, NGF | NAPRT 848/4885KDM4E 3530/4885TDP1 1343/4885 |
| US-10010539-B2 | Pyrazole, triazole and tetrazole orexin receptor antagonists | HCRTR2, HCRTR1, NPY5R | NAPRT 1839/4885KDM4E 3243/4885TDP1 4160/4885 |
| US-20080161290-A1 | Serine hydrolase inhibitors | SERPINB1, ELANE, EPX | NAPRT 1325/4885KDM4E 1816/4885TDP1 676/4885 |
| US-20170320865-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NAPRT 1683/4885KDM4E 2264/4885TDP1 4549/4885 |
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | NAPRT 1097/4885KDM4E 4131/4885TDP1 2804/4885 |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NAPRT 1840/4885KDM4E 2571/4885TDP1 4734/4885 |
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | H1-10, H1-4, H1-3 | NAPRT 4526/4885KDM4E 1779/4885TDP1 2706/4885 |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | ABCB11, ABCB1, ABCC5 | NAPRT 388/4885KDM4E 4529/4885TDP1 3251/4885 |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | NAPRT 928/4885KDM4E 1738/4885TDP1 2692/4885 |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NAPRT 2399/4885KDM4E 2973/4885TDP1 4837/4885 |
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | NAPRT 1486/4885KDM4E 143/4885TDP1 1383/4885 |
| US-20160152569-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | NAPRT 2354/4885KDM4E 411/4885TDP1 3293/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | NAPRT 2525/4885KDM4E 2533/4885TDP1 4134/4885 |
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | APP, APBA1, PSEN1 | NAPRT 2232/4885KDM4E 4658/4885TDP1 2827/4885 |
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | NAPRT 1276/4885KDM4E 654/4885TDP1 284/4885 |
| US-20230106583-A1 | HETEROARYL COMPOUNDS | YAP1, MYC, HRAS | NAPRT 2637/4885KDM4E 1662/4885TDP1 1672/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | NAPRT 234/4885KDM4E 922/4885TDP1 639/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | NAPRT 113/4885KDM4E 1056/4885TDP1 1883/4885 |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | NAPRT 2475/4885KDM4E 215/4885TDP1 1585/4885 |
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | NAPRT 1193/4885KDM4E 1209/4885TDP1 2614/4885 |
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | NAPRT 1698/4885KDM4E 1832/4885TDP1 4656/4885 |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | NAPRT 1748/4885KDM4E 2007/4885TDP1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.